Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
03/2010
03/30/2010US7687059 Systems and methods for treating patients with processed lipoaspirate cells
03/30/2010CA2457444C 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
03/30/2010CA2452920C Benzo [g] quinoline derivatives for treating glaucoma and myopia
03/30/2010CA2442245C 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
03/30/2010CA2436667C Novel bioactive substance
03/30/2010CA2420894C Thienopyrimidines
03/30/2010CA2409665C Novel composition
03/30/2010CA2360685C Methods for restoring and/or enhancing accommodation in pseudo phakia
03/30/2010CA2356404C Method for accelerating the rate of mucociliary clearance
03/25/2010WO2010033045A1 Compositions and methods for prevention or treatment of beta amyloid deposition
03/25/2010WO2010032786A1 Transgenic animal
03/25/2010WO2010032140A2 Pharmaceutical compositions and related methods of delivery
03/25/2010WO2010032073A1 Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
03/25/2010WO2010031248A1 Thiazolium salt compound and the use of treating the protein aging disease
03/25/2010WO2010008777A3 Fused azabicyclic pyridines
03/25/2010WO2010008733A3 Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use
03/25/2010US20100076069 Forskolin dosing regimen in open angle glaucoma and patient compliance methods thereof
03/25/2010US20100076068 Aminoalcohol Derivatives and Their Therapeutic Use
03/25/2010US20100076045 Stabilized pharmaceutical sub-micron suspensions and methods of forming same
03/25/2010US20100076020 Quinolynylmethylimidizoles as therapeutic agents
03/25/2010US20100075986 Oxophenyl-Cyclohexyl-Propanolamine Derivatives, Production And Use Thereof In Therapeutics
03/25/2010US20100075941 Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
03/25/2010US20100075931 Substituted oxazole ketone modulators of fatty acid amide hydrolase
03/25/2010US20100075916 Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases
03/25/2010US20100075910 Synthetic peptide amides and dimeric forms thereof
03/25/2010US20100075898 N-terminal vdac variants and uses thereof
03/25/2010US20100074957 Intraocular formulation
03/25/2010US20100074882 Methods and compositions for preserving the viability of photoreceptor cells
03/25/2010US20100074871 Probiotic infant products
03/25/2010CA2737738A1 Heterocyclic carboxamide compounds
03/25/2010CA2737456A1 Pharmaceutical compositions and related methods of delivery
03/24/2010EP2166096A2 Moraxella (Branhamella) catarrhalis antigens
03/24/2010EP2166087A2 FAD4, FAD5, FAD5-2 et FAD6, fatty acid desaturase family members and uses thereof
03/24/2010EP2166010A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
03/24/2010EP2166009A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
03/24/2010EP2166008A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
03/24/2010EP2166003A1 Excitatory amino acid receptor antagonists
03/24/2010EP2165605A1 Use of a ribonuclease of the T2 family having actin-binding activity for inhibiting and/or reversing proliferation
03/24/2010EP1809270B1 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
03/24/2010CN101679988A Fusion proteins binding to growth factors
03/24/2010CN101679328A Prophylactic or therapeutic agent for age-related macular degeneration
03/24/2010CN101678065A Vaccine therapy for choroidal neovascularization
03/24/2010CN101678042A Suspension for visualization of transparent tissue in eye
03/24/2010CN101678006A Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
03/24/2010CN101677974A Neramexane for the treatment of nystagmus
03/24/2010CN101675939A Traditional Chinese medicine for treating eye keratitis and preparation method
03/24/2010CN101675927A therapeutic molecules and methods-1
03/24/2010CN100595211C Angiopoietin-2 specific binding agents
03/24/2010CN100594939C Medicament sustained-release carrier for eyes with cooperation treatment function
03/24/2010CN100594913C Medicine combination for curing diabetes and complication thereof and the preparing method and purpose
03/24/2010CN100594901C Aqueous ophthalmic suspension of crystalline rebamipide
03/24/2010CN100594899C Sustained release system and method for ocular delivery of carbonic anhydrase inhibitors
03/23/2010US7683164 Nucleic acid derivatives
03/23/2010US7683094 2-(2-((2R)-2-heptylaminomethyl-5-oxopyrrolidin-1-yl)ethylthio)-1,3-thiazole-4-carboxylic acid; EP2 and/or EP4 receptor agonist; immune disease; antiallergens; alopecia; dysmenorrhea; erectile dysfuncction; antiarthritic agents; liver, respiratory, vascular, urogenital disorder
03/23/2010US7683078 Neuronal disorders, autoimmune diseases, cancer, cardiovascular diseases; such as 4-Chloro-N-{5-[1-(4-trifluoromethyl-benzyl)-piperidin-3-ylsulfamoyl]-25 thiophen-2-ylmethyl)-benzamide
03/23/2010US7683074 Antiinflammatory agents; antiallergens; neurodegrative disease ; autoimmune disease; antiarthritic agents
03/23/2010CA2460177C 3-substituted-4-pyrimidone derivatives
03/23/2010CA2437563C Photodynamic therapy of occult age-related macular degeneration
03/23/2010CA2389767C Quinazoline derivatives as vegf inhibitors
03/23/2010CA2352436C Polymorphs of telmisartan, processes for preparing them and their use in the preparation of a pharmaceutical composition
03/18/2010WO2010030757A2 Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
03/18/2010WO2010030725A1 Compositions comprising polymers having amino sugar units and methods of making and using same
03/18/2010WO2010029986A1 Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester structure introduced therein as substituent
03/18/2010WO2010029364A1 Compounds
03/18/2010WO2010029352A1 Treatment of fibrotic eye disorders using an mmp2 inhibitor
03/18/2010WO2010029350A1 Treatment of fibrotic eye disorders
03/18/2010WO2010028769A1 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
03/18/2010WO2010011622A9 Ophthalmic gallium compositions and methods of their use
03/18/2010WO2009133552A3 Methods of treating ophthalmic disorders
03/18/2010US20100069482 Gel useful for the delivery of ophthalmic drugs
03/18/2010US20100069409 "novel compounds"
03/18/2010US20100069361 Fused Thiazole Derivatives as Kinase Inhibitors
03/18/2010US20100069343 Methods of predicting steroid responsiveness with Il-1RII
03/18/2010US20100069335 Prevention and Treatment of Ophthalmic Complications of Diabetes
03/18/2010US20100069315 Method and medicament for treating ocular infections
03/18/2010US20100068298 Nutritional supplement composition for treatment of ocular diseases
03/18/2010US20100068177 Methods of organ regeneration
03/18/2010US20100068141 Use of heat shock to treat ocular disease
03/18/2010CA2736380A1 Compositions comprising polymers having amino sugar units and methods of making and using same
03/18/2010CA2735417A1 Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivatives containing phenyl group having sulfonic acid ester structure introduced therein as substituent
03/18/2010CA2735368A1 Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
03/18/2010CA2731660A1 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
03/17/2010EP2163643A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
03/17/2010EP2163548A1 Prophylactic or therapeutic agent for age-related macular degeneration
03/17/2010EP2162124A1 Neramexane for the treatment of nystagmus
03/17/2010EP1315502B1 Method for treating erectile dysfunction and increasing libido in men
03/17/2010CN101674824A Treatment of age-related macular degeneration using inhibitors of complement factor d
03/17/2010CN101674807A Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
03/17/2010CN101671393A Angiopoietin-2 specific binding agents
03/17/2010CN101670057A Compound ear dropping liquid for treating suppurative otitis media
03/17/2010CN101670052A Drug for treating Meniere disease and preparation method thereof
03/17/2010CN101670030A External medicine for treating suppurative otitis media and preparation method thereof
03/17/2010CN101670019A Complex preparation having radiation-resisting and eyesight-protecting functions
03/17/2010CN101669996A Method for preparing vision-health buccal tablet
03/17/2010CN101669909A Biological adhesive liposome preparation for eyes and preparation method thereof
03/17/2010CN101669901A Liquid preparation for dosing eyes and method for making the same
03/17/2010CN100594027C Percutaneous medicine of strychnine, toxiferine, securinine and salt thereof
03/16/2010US7678834 Substituted 4-aminocyclohexanol compounds
03/16/2010US7678810 activin receptor-like kinase 5 (ALK5) (which is a TGF- beta type I receptor) inhibitor ; glomerulonephritis, diabetic nephropathy, hepatic fibrosis, liver cirrhosis, pulmonary fibrosis, or alopeciarosis; hair growth stimulant
03/16/2010US7678792 e.g. 3-(5-amino-2-methylphenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one; protein kinase inhibitor; antiinflammatory, anticarcinogenic, antiallergen, antidiabetic, antiischemic, hypotensive agent
1 ... 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 ... 531